All lobbying filings

TIBER CREEK GROUP

TIBER CREEK GROUP filed a Q3 report for ALNYLAM PHARMACEUTICALS, INC. on October 19, 2026, reporting $60,000 in lobbying income.

Lobbying for ALNYLAM PHARMACEUTICALS, INC. · Biopharmaceuticals.

All filings by TIBER CREEK GROUP · Everything ALNYLAM PHARMACEUTICALS, INC. has reported

Filing · LD-2 quarterly report Q3 report

Reporting period

3rd Quarter 2026

July 1 - Sep 30 · Posted Oct 19, 2026

Income

$60,000

What the client paid this registrant for the period.

Client based in

Massachusetts

Official filing document

Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 1

Medicare/Medicaid

Issues related to H.R. 1672 - Maintaining Investments in New Innovation Act; Issues related to Medicare and Medicaid drug pricing.

Bills named in this filing 1

H.R. 1672
Maintaining Investments in New Innovation Act

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.